Roderick MacKinnon

Roderick MacKinnon
MacKinnon in 2014
Roderick MacKinnon
Born	2/19/1956
Birthplace	Burlington, Massachusetts, U.S.
Nationality	American
Occupation	Biophysicist, neuroscientist, professor
Title	John D. Rockefeller Jr. Professor of Molecular Neurobiology and Biophysics
Employer	Rockefeller University
Known for	Determining the structure and mechanism of ion channels
Education	M.D. (Tufts University School of Medicine)
Spouse(s)	Jue Chen (m. 2017)
Awards	Nobel Prize in Chemistry (2003), Louisa Gross Horwitz Prize (2003)
Website	http://lab.rockefeller.edu/mackinnon/

Roderick MacKinnon (born February 19, 1956) is an American biophysicist, neuroscientist, and businessman who fundamentally transformed the scientific understanding of how ions move across cell membranes. A professor of molecular neurobiology and biophysics at Rockefeller University, MacKinnon was awarded the Nobel Prize in Chemistry in 2003, shared with Peter Agre, for his groundbreaking work on the structure and operation of ion channels—the protein-based gates embedded in cell membranes that control the flow of potassium, sodium, and other ions essential to nerve impulse transmission, muscle contraction, and numerous other biological processes. His career trajectory is notable for its unconventional path: MacKinnon trained and practiced as a medical doctor before abandoning clinical medicine to pursue research in biophysics, a field in which he had no formal graduate training. He taught himself X-ray crystallography, the technique that would become central to his Nobel Prize-winning discoveries. Beyond academic research, MacKinnon has also ventured into entrepreneurship, co-founding a biotechnology company focused on neuromuscular disorders. His research continues to yield insights into the fundamental biophysics of voltage-dependent ion channels, with recent publications advancing the understanding of voltage-sensor movements and pore gating mechanisms.

Early Life

Roderick MacKinnon was born on February 19, 1956, in Burlington, Massachusetts, a suburb northwest of Boston. He grew up in a family environment that valued education and hard work. His father, Roderick M. MacKinnon Sr., was a postal worker who raised his family in the greater Boston area.

MacKinnon's early interests were broad, and he did not initially display a singular focus on the sciences that would later define his career. Growing up in Massachusetts during the 1960s and 1970s, he was exposed to the academic culture of the greater Boston area, home to numerous universities and research institutions. His path toward science was not immediately apparent, and the trajectory that would eventually lead him to a Nobel Prize was circuitous rather than direct.

As a young man, MacKinnon developed an interest in understanding how things worked at a fundamental level, though this curiosity would take years to find its ultimate expression in the study of ion channel proteins. His upbringing in Burlington provided a stable foundation, and his family's support enabled him to pursue higher education at a time when the biological sciences were undergoing rapid transformation with the advent of molecular biology and structural biology techniques.

Education

MacKinnon attended Brandeis University in Waltham, Massachusetts, where he completed his undergraduate studies, graduating in 1978. Following his undergraduate education, he enrolled at Tufts University School of Medicine, where he earned his Doctor of Medicine (M.D.) degree.

Continued Research at Rockefeller University

Following the Nobel Prize, MacKinnon continued his research program at Rockefeller University, expanding the scope of his investigations into ion channel biophysics. His laboratory pursued structural and functional studies of increasingly complex ion channel proteins, including voltage-gated potassium channels, which contain voltage-sensing domains that detect changes in membrane potential and translate them into conformational changes that open or close the channel pore.

In 2022, MacKinnon's laboratory published research in the Proceedings of the National Academy of Sciences (PNAS) examining voltage-sensor movements in the Eag Kv channel under an applied electric field. This study advanced the understanding of how voltage-dependent ion channels regulate pore opening by sensing membrane voltage, a process that underlies the propagation of electrical signals in the nervous system.

In 2025, MacKinnon's laboratory continued to publish research on ion channel biophysics. A study published in the National Institutes of Health repository investigated electric field-induced pore constriction in the human Kv2.1 channel, further elucidating the mechanisms by which transmembrane voltage regulates gating in voltage-dependent ion channels. Also in 2025, his group published work in PNAS on the self-assembly and modulation of higher-order transient protein structures, examining how membrane protein homo-oligomers form through cohesive self-interactions.

In October 2022, MacKinnon delivered a Wednesday Afternoon Lecture Series (WALS) lecture at the National Institutes of Health, where he described the biophysics and biology of potassium ion channels to a broad scientific audience.

Entrepreneurship: Flex Pharma

In addition to his academic career, MacKinnon entered the biotechnology business sector. In 2014, he was involved in the founding of Flex Pharma, a biotechnology company that raised approximately $40 million in initial funding to develop treatments for muscle cramps. The company was co-founded with Christoph Westphal and was based on MacKinnon's research into the neuromuscular mechanisms underlying muscle cramps.

MacKinnon's interest in muscle cramps stemmed in part from his personal experience as an avid athlete and endurance sports enthusiast. He had observed that certain spicy substances appeared to alleviate muscle cramps, leading him to investigate the underlying neuroscience. His research suggested that muscle cramps were driven by hyperactive motor neurons rather than dehydration or electrolyte imbalance, as was commonly believed, and that activating certain sensory ion channels (specifically TRP channels) in the mouth and esophagus could inhibit the motor neuron activity responsible for cramping.

Flex Pharma developed a consumer product called HOTSHOT, a spicy beverage marketed to athletes for the prevention and treatment of exercise-associated muscle cramps. The company also pursued pharmaceutical development, conducting clinical trials for a drug candidate targeting muscle cramps and spasticity.

Flex Pharma completed an initial public offering (IPO) that raised approximately $86 million. However, the company later encountered setbacks, discontinuing its mid-stage clinical trials, reducing its workforce, and considering a sale of the company to remain viable. Securities filings from 2018 documented the company's financial difficulties and strategic review process.

Personal Life

MacKinnon married Jue Chen, a fellow structural biologist and professor at Rockefeller University, in 2017. Chen is known for her research on ABC transporters, another class of membrane proteins, and holds the William E. Ford Professor position at Rockefeller University. The couple represents an unusual pairing of two prominent structural biologists at the same institution.

MacKinnon is known to be an avid endurance athlete, with interests in long-distance running and cycling. His athletic pursuits directly influenced his scientific interest in muscle cramps, which led to the founding of Flex Pharma and the development of the HOTSHOT product.

His father, Roderick M. MacKinnon Sr., passed away on February 6, 2026, in New York. The elder MacKinnon, who was known as "Rod" to friends and family, had been a longtime resident of the greater New York area in his later years.

Recognition

MacKinnon's scientific contributions have been recognized with numerous honors and awards, the most prominent being the 2003 Nobel Prize in Chemistry. The Nobel committee cited his work for providing "structural and mechanistic studies of ion channels," recognizing that his research had revealed fundamental principles of how living organisms generate and transmit electrical signals.

In addition to the Nobel Prize, MacKinnon received the Louisa Gross Horwitz Prize from Columbia University in 2003, an award that has frequently preceded the Nobel Prize for its recipients. He was also elected as a foreign member of the Royal Netherlands Academy of Arts and Sciences (KNAW), recognizing his international scientific stature.

Brandeis University, MacKinnon's undergraduate alma mater, awarded him an honorary degree (H'05) in 2005, recognizing the achievements of one of its most distinguished alumni.

MacKinnon's position as a Howard Hughes Medical Institute investigator at the time of his Nobel Prize further reflected the esteem in which his research program was held within the biomedical research community. The HHMI investigator appointment is one of the most competitive and prestigious research funding mechanisms in the United States.

His work at Brookhaven National Laboratory's synchrotron facility also contributed to the recognition of that institution's role in enabling Nobel Prize-caliber research in structural biology.

Legacy

MacKinnon's determination of the first high-resolution structure of a potassium ion channel in 1998 is considered a landmark achievement in structural biology and biophysics. The work provided the first atomic-level explanation for how ion channels achieve their remarkable selectivity, solving a problem that had been debated by physiologists and biophysicists for decades. The potassium channel structure became one of the most reproduced images in modern biochemistry and neuroscience textbooks, and it established the structural framework for understanding an entire class of membrane proteins.

The practical implications of MacKinnon's work extend into medicine and pharmacology. Ion channels are the targets of numerous drugs, including local anesthetics, antiarrhythmic agents, and antiepileptic medications. By providing detailed structural information about how these channels work, MacKinnon's research created a foundation for rational drug design efforts aimed at developing more effective and selective therapeutics for cardiac arrhythmias, epilepsy, pain, and other conditions in which ion channel dysfunction plays a role.

MacKinnon's career path—from practicing physician to self-taught crystallographer to Nobel laureate—has also served as an example of the value of nontraditional career trajectories in science. His story demonstrates that formal credentials in a specific discipline are not always a prerequisite for making transformative contributions to that field, provided one possesses the intellectual drive and determination to master the necessary techniques independently.

His ongoing research program at Rockefeller University, with publications continuing into 2025 on topics such as voltage-sensor dynamics and higher-order transient protein structures, indicates that MacKinnon remains an active and productive scientist more than two decades after receiving the Nobel Prize.

Related biographies

• Paul Greengard — Neuroscientist
• Thomas A. Steitz — Biochemist
• Joachim Frank — Biophysicist
• Thomas Steitz — Biochemist
• Venkatraman Ramakrishnan — Structural Biologist
• Roger Kornberg — Structural Biologist